Introduction {#Sec1}
============

Severe sepsis in critically ill infant in the intensive care unit is a major healthcare problem associated with high morbidity and mortality. In recent years the growing drug resistance in nosocomial gram-negative bacteria has resulted in treatment challenges for physicians, mostly for pediatricians \[[@CR1], [@CR2]\]. Despite the rising relevance of *Pseudomonas aeruginosa* infections in adults, only a few studies have evaluated this condition in pediatric population \[[@CR3], [@CR4]\]. This case report describes the efficacy and safety of glycylcycline antibiotic tigecycline as a salvage therapy for an infant with severe sepsis caused by multi-drug-resistant *Pseudomonas aeruginosa*.

Case Presentation {#Sec2}
=================

A 5-month-old boy with patent arterial duct, congestive heart failure, and respiratory syncytial virus infection was admitted to pediatric intensive care unit for respiratory failure. While intubated on mandatory ventilation, the patient developed sepsis and hemodynamic instability requiring inotropic support with catecholamines. Empiric therapy with meropenem, gentamicin, and fluconazole was initiated. To stabilize hemodynamics, transcatheter occlusion of patent arterial duct was performed. Microbial specimens from upper respiratory tract, bronchoalveolar lavage, and urine showed a presence of multi-drug-resistant *Pseudomonas aeruginosa*. Oropharyngeal swab was taken by inserting swab into the posterior pharynx and tonsillar areas and rubbed over both tonsils and posterior wall of oropharynx while avoiding contact with other areas of the oral cavity. Nasopharyngeal swab was taken by inserting swab through the nares parallel to the palate until resistance was indicating contact with the nasopharynx (approximately the distance equivalent to that from the ear to the nostril of the patient). Then, the swab was rubbed and left in place for several seconds to absorb secretions. Blood cultures remained negative. Based on minimum inhibitory concentration, the therapy was changed to amikacin and colistin. Meropenem was discontinued due to resistance. Three days later, the patient clinical conditions deteriorated. Low cardiac output syndrome was treated by combination of epinephrine, norepinephrine, and terlipressin and acute respiratory distress syndrome by high frequency oscillatory ventilation, inhaled nitric oxide, and pulmonary surfactant. In case of serious sepsis and carbapenem resistance, high-dose meropenem (40 mg/kg every 8 h) was considered but could not be administered because of oligoanuria. Thus, the dose of 20 mg/kg was given on the first day followed by 10 mg/kg for the next 28 days. Organ dysfunction involved also other systems, and the patient developed pancytopenia, hepatopathy with cholestasis, paralytic ileus, and renal failure with anuria. Despite combined antibiotic therapy with meropenem, amikacin, and colistin, procalcitonin and C-reactive protein increased to 85 ng/ml and 482 mg/l, respectively (Fig. [1](#Fig1){ref-type="fig"}). Because of life-threatening condition, tigecycline was added to the therapy with permission and agreement of the parents. Tigecycline was administered intravenously twice daily with a loading dose of 2 mg/kg and then 1 mg/kg. Within 48 h, inflammatory markers started to decrease and cardiac output improved. Tigecycline therapy continued for 13 days without adverse effects. Then, amikacin, colistin, and meropenem were gradually discontinued. Catecholamines were reduced. Renal and hepatic impairment improved. Patient was successfully extubated on the 28th day of hospitalization. Patient fully recovered and was discharged from intensive care unit after 39 days.Fig. 1Inflammatory markers in an infant with multi-organ failure and severe sepsis caused by multi-drug-resistant *Pseudomonas aeruginosa*

Discussion and Conclusions {#Sec3}
==========================

In the recent era, raising bacterial resistance to standard antibiotics resulted in limited options for the treatment of serious infections. One of the most common multi-drug-resistant bacteria is a gram-negative non-fermenting bacillus, *Pseudomonas aeruginosa*, being the major infectious agent responsible for ventilator-associated pneumonia, catheter-associated urinary tract infections, surgical site infections, and intra-abdominal infections \[[@CR1]\]. The risk of developing infection with multi-drug-resistant pathogens depends on the presence of risk factors (hospitalization longer than 5 days, recent hospitalization within 90 days, recent antibiotic therapy, residence in a nursing home, need for chronic care outside the hospital) \[[@CR5]\]. The risk of intrinsic and acquired resistance is an important factor while selecting empiric or directed therapy. Common resistance to standard antibiotics in *Pseudomonas aeruginosa* infections limits the therapeutic options. The antipseudomonal antibiotic agents include penicillin-beta-lactamase combinations (piperacillin-tazobactam), cephalosporins, monobactams, fluoroquinolones, carbapenems, aminoglycosides, and polymyxins. In severe infections, combination of antibiotics is advocated \[[@CR2], [@CR6]\]. In some cases, antibiotic combinations may include agent, to which bacteria show microbial resistance \[[@CR7]\]. Synergistic effects against multi-drug-resistant bacteria, including *Pseudomonas aeruginosa*, have been revealed for double and triple antibiotic combinations including an aminoglycoside, meropenem, colistin, a fluoroquinolone, a macrolide, or rifampin \[[@CR8], [@CR9]\]. Colistin with meropenem may also be considered salvage therapy for carbapenem-resistant *Pseudomonas aeruginosa* strains \[[@CR10]\]. In our patient case, we presumed that returning meropenem to the therapy would result in synergic effect with amikacin and colistin. However, despite the combination therapy, patient condition deteriorated with worsening of multi-organ failure. Adding a tigecycline into the therapy resulted in inflammatory markers decline and improvement of clinical condition.

In adults, there are many clinical trials with the use of tigecycline as a broad-spectrum antibiotic. In infants, only a few cases of tigecycline use have been reported because of side effects that include nausea, vomiting, diarrhea, acute pancreatitis, teeth discoloration, and neutrophil engraftment delay \[[@CR3], [@CR11]\]. However, the recent data show that tigecycline may represent a considerable treatment option in life-threatening infectious complications in pediatric patients as a part of combination therapy. Although *Pseudomonas aeruginosa* is not reliably inhibited by tigecycline, it seems to be a highly active antimicrobial agent in critically ill and immunocompromised pediatric patients \[[@CR12]\].

Iosifidis et al. \[[@CR13]\] conducted a retrospective chart review of 13 children treated with tigecycline. The youngest child was 2.5 months old. Tigecycline was used for managing bacteremia, pneumonia, and three unspecified infections. Song et al. \[[@CR4]\] described a case series of 22 pediatric patients suffering from serious infections after surgery with median age of 7.5 months who received an initial dose of 1.5 mg/kg and then 1.2 mg/kg of tigecycline every 12 h. Median duration of treatment was 17 days and 86% of patients had positive response. Emiroglu et al. \[[@CR14]\] described a 5-month-old infant with ventriculo-peritoneal shunt meningitis. Tigecycline dose of 1.2 mg/kg twice a day was administered for 20 days. In our patient, tigecycline was used as a salvage therapy in combination with other antipseudomonal antibiotics in a patient with sepsis-induced multi-organ failure. Tigecycline was given for 13 days twice daily with the initial dose of 2 mg/kg and maintenance dose of 1 mg/kg. We observed no adverse effects during therapy. Tigecycline did not eradicate *Pseudomonas aeruginosa*, although inflammatory markers decreased which may be raised initially because of other conditions rather than sepsis. Although *Pseudomonas aeruginosa* colonization persisted, inflammatory markers decreased and patient fully recovered. We can conclude that cardiac failure in an infant with congenital heart disease can be complicated with respiratory failure due to viral infection and, subsequently, with multi-organ failure in case of Pseudomonas sepsis. Based on our patient case, we suggest that tigecycline in combination with other standard antipseudomonal antibiotics may be considered in children for the management of severe multi-drug-resistant bacteria infections when conventional treatment has failed.
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